Results 11 to 20 of about 26,436 (212)

Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study [PDF]

Frontiers in Oncology
ObjectiveThe aim of this study was to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) and lenvatinib in HCC patients with PVTT (Vp2-3), thus providing a safe and ...
Haohao Lu, Haohao Lu, Chuansheng Zheng, Chuansheng Zheng, Bin Liang, Bin Liang, Xiangwen Xia, Xiangwen Xia, Hongjie Fan, Hongjie Fan   +9 more
doaj   +2 more sources

Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer

Cancer Immunology, Immunotherapy
Introduction Tyrosine kinase inhibitors, including lenvatinib approved for advanced non-medullary thyroid cancer (TC), affect the immune system. As tumor-related inflammation contributes to TC pathogenesis, this study assesses the immunomodulatory ...
Prashant Changoer, Chunying Peng, Pepijn van Houten, Liesbeth van Emst, Janneke E. W. Walraven, Petronella B. Ottevanger, Martin Jaeger, Romana T. Netea-Maier   +7 more
doaj   +2 more sources

Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer

Endocrinology, Diabetes & Metabolism Case Reports, 2019
We report a case of rapid pleural effusion after discontinuation of lenvatinib. A 73-year-old woman was diagnosed with poorly differentiated thyroid cancer with right pleural metastasis.
Taisuke Uchida, Hideki Yamaguchi, Kazuhiro Nagamine, Tadato Yonekawa, Eriko Nakamura, Nobuhiro Shibata, Fumiaki Kawano, Yujiro Asada, Masamitsu Nakazato   +8 more
doaj   +2 more sources

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma, 2023
Meng Tao,1,2 Jing Han,3 Juanyi Shi,1,2 Hao Liao,1,2 Kai Wen,1,2 Weidong Wang,1,2 Sintim Mui,1,2 Huoming Li,1,2 Yongcong Yan,1,2 Zhiyu Xiao1,2 1Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120 ...
Tao M, Han J, Shi J, Liao H, Wen K, Wang W, Mui S, Li H, Yan Y, Xiao Z   +9 more
doaj   +1 more source

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial [PDF]

, 2023
Background Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages.
Hiromitsu Kumada, Dutcus, Corina, Jee Hyun Kim, Galle, Peter R, Shukui Qin, Richard S Finn, Julien Edeline, Edeline, Julien, Merle, Philippe, Masafumi Ikeda, Kim, Jee Hyun, Peter R Galle, Masi, Gianluca, Abby B Siegel, Baek-Yeol Ryoo, Kudo, Masatoshi, Ann-Lii Cheng, Ikeda, Masafumi, Mody, Kalgi, Shuichi Kaneko, Cheng, Ann-Lii, Qin, Shukui, Philippe Merle, Wang, Anran, Gianluca Masi, Siegel, Abby B, Ryoo, Baek-Yeol, Meyer, Tim, Mariusz Kwiatkowski, Lim, Ho Yeong, Llovet, Josep M, Corina Dutcus, Tim Meyer, Valeriy Breder, Kaneko, Shuichi, Ho Yeong Lim, Leonid Dubrovsky, Ruocai Xu, Anran Wang, Xu, Ruocai, Ren, Zhenggang, Josep M Llovet, Breder, Valeriy, Zhenggang Ren, Dubrovsky, Leonid, Kwiatkowski, Mariusz, Kumada, Hiromitsu, Masatoshi Kudo, Kalgi Mody, Finn, Richard S   +49 more
core   +4 more sources

Lenvatinib and Palbociclib [PDF]

Hospital Pharmacy, 2015
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A, Solimando, J Aubrey, Waddell
openaire   +2 more sources

Recurrent TFE3-Rearranged Renal Cell Carcinoma Responding to Pembrolizumab Plus Lenvatinib After Postoperative Pembrolizumab: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction TFE3‐rearranged renal cell carcinoma (RCC) is rare, and evidence guiding systemic therapy is limited. Case Presentation A 25‐year‐old man with gross hematuria had a left renal tumor with hilar lymph node metastasis. Robot‐assisted radical nephrectomy and hilar lymph node dissection were performed.
Fujimoto M, Sano T, Sano Y, Inoue S, Matsuo K, Kimura T, Ishida S, Zennami K, Matsukawa Y, Akamatsu S.   +9 more
europepmc   +2 more sources

Curative-Intent Pancreatectomy for Pancreatic Metastasis From Renal Cell Carcinoma 30 Years After Nephrectomy Following Lenvatinib Plus Pembrolizumab Therapy: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction Renal cell carcinoma (RCC) is the most common primary site of pancreatic metastases, and complete resection confers a favorable prognosis. Lenvatinib plus pembrolizumab (LEN + PEM) is standard first‐line therapy for advanced RCC; however, induction therapy before resection of pancreatic metastasis has not been reported.
Kaneko Y, Kotorii R, Shimizu K, Miura K, Nakanishi Y, Nakamura K, Hattori S, Yagi Y, Nishiyama T, Momma T.   +9 more
europepmc   +2 more sources

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma [PDF]

, 2022
Lenvatinib is a multi-targeted tyrosine kinase inhibitor available for the treatment of unresectable hepatocellular carcinoma (HCC). We herein report an 84-year-old-man with interstitial pneumonia caused by lenvatinib.
709, Nishioka, Yasuhiko, 吾妻, 雅彦, タカハシ, ナオキ, 1414, Azuma, Masahiko, 798, Naito, Nobuhito, 997, 799, Nishimura, Haruka, ムラカミ, コウジン, 内藤, 伸仁, Mima, Masato, イマクラ, タケシ, カガワ, コウゾウ, ニシオカ, ヤスヒコ, ノキハラ, ヒロシ, 高山, 哲治, 90724089, Koyama, Kazuya, 287, 1542, ナイトウ, ノブヒト, コヤマ, カズヤ, 294227/profile-ja.html, 20556807, 10284994, 河野, 弘, タカヤマ, テツジ, 70274199, Tomonari, Tetsu, Takayama, Tetsuji, トモナリ, テツ, ミマ, マサト, 362727/profile-ja.html, Kagawa, Kozo, 軒原, 浩, 60062/profile-ja.html, アヅマ, マサヒコ, 友成, 哲, 978, サトウ, セイダイ, 1637, 西岡, 安彦, 294226/profile-ja.html, カワノ, ヒロシ, 169695/profile-ja.html, 80325282, 香川, 耕造, 佐藤, 正大, Nokihara, Hiroshi, ニシムラ, ハルカ, Takahashi, Naoki, Kawano, Hiroshi, Imakura, Takeshi, 小山, 壱也, Satou, Seidai, 80530899, Murakami, Kojin   +59 more
core   +2 more sources

A useful case of tumor resection and monitoring the blood concentration at lenvatinib therapy for multiple hepatocellular carcinoma.

, 2021
症例は慢性C 型肝炎に罹患し飲酒習慣もある60 歳代男性で，原発性肝細胞癌の一部に破裂予防の肝動脈塞栓術施行後，lenvatinib 8 mg/日を開始した．約1 カ月で腫瘍に感染し，抗生剤治療不応かつ経皮的ドレナージ困難にて，lenvatinib を一週間休薬し，開腹下感染腫瘍切除術を施行した．術後創部治癒に問題なく，lenvatinib を4 mg/日で再開したが，肝障害，倦怠感，食思不振で35 日間休薬した．dexamethasone 併用して再開し，8 mg/日まで増量したが動脈血流減少せず ...
谷, 眞至, 0000-0001-6245-4583, 安藤, 朗, TERADA, Tomohiro, WAKASUGI, Yoshinori, 674, 696, 675, 0000-0003-1270-6003, 90252395, OSAKI, Rie, 778, 10324641, 0000-0001-8533-2669, 40737665, 90792820, 寺田, 智祐, IIDA, Hiroya, FUJIMOTO, Takehide, 6103, 30733901, 大崎, 理英, 藤本, 剛英, 60865707, 若杉, 吉宣, 野田, 哲史, TANI, Masaji, 飯田, 洋也, 2854, 644, NODA, Satoshi, 844, ANDOH, Akira, 60236677   +33 more
core   +1 more source